The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

On Monday, the FDA said the company could continue testing its combination ... its full-year outlook when it announced its ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

The U.S. vaccine maker now expects between $175 million ... including an experimental COVID-flu combination shot, which got ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Bird flu has infected ... Pharmaceuticalscategory US FDA declines full approval for Intercept's liver disease drug 6:18 PM ...

More doctors are looking out for the condition. But that’s not enough to explain the increase in the nation’s overall ...

The FDA concluded that the event was not related to the vaccine. Robert Walker ... China has reported seven more H9N2 avian ...

Across California, public health and pest control authorities are facing a new reality as the Aedes mosquitoes bring the ...